Atrium Therapeutics, Inc. Common Stock (RNA) — Cash Flow Reinvestment Rate
Atrium Therapeutics, Inc. Common Stock (RNA) has a Cash Flow Reinvestment Rate of 3.15x as of December 2023, reinvesting $51.90 Million (capex $863.00K plus investments $51.04 Million) from operating cash flow of $16.50 Million. See Atrium Therapeutics, Inc. Common Stock (RNA) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Atrium Therapeutics, Inc. Common Stock Cash Flow Reinvestment Rate (2019–2019)
Historical reinvestment intensity for Atrium Therapeutics, Inc. Common Stock across 1 annual periods. For the full cash flow conversion analysis, see Atrium Therapeutics, Inc. Common Stock (RNA) cash flow conversion.
Annual Cash Flow Reinvestment Rate for Atrium Therapeutics, Inc. Common Stock (2019–2019)
Year-by-year capital reinvestment analysis for Atrium Therapeutics, Inc. Common Stock. See RNA financial flexibility score to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2019 | 0.19x | $470.00K | $2.49 Million | $235.00K | — |